The Injective ecosystem experienced significant developments with two major announcements that could reshape its market position. According to reports from AMBCrypto, the Injective Foundation launched the Trench Treasury to fund projects and communities that help the ecosystem grow, while Canary Capital filed with the SEC for a staked INJ ETF. The Trench Treasury initiative aims to help projects with organic growth, fair launches, real liquidity, and rewards for loyal ecosystem participants, with a focus on supporting smaller teams building with INJ rather than just established projects.
The Canary Capital filing represents a significant milestone for Injective's institutional adoption strategy. As reported by AMBCrypto, the fund seeks to offer exposure to Injective while earning additional INJ through active participation in the staking program. The ETF is expected to launch before 2027, according to Injective's CEO, Erick Chen. If approved by the SEC, the ETF positions INJ to greater institutional exposure, especially as spot ETFs have gained momentum in the market.
The developments have already influenced market sentiment and capital deployment patterns. According to AMBCrypto, Injective's Spot Netflow dropped to -$1.12 million, marking a reversal from positive territory recorded the previous day. Similarly, Injective's Perpetual Volume rose to $54 million from $53 million the previous day, suggesting renewed interest in leveraged positions. These capital flow patterns indicate increased investor activity incentivized by the new developments.
Despite the positive developments, Injective's technical indicators suggest continued consolidation pressure. As reported by AMBCrypto, the altcoin has continued to hover between $7.5 and $7.7, with momentum indicators leaning bearish. The Moving Average Convergence Divergence (MACD) has been on a downward trajectory since forming a bearish crossover a week ago, while Stochastic (Stoch) also formed a bearish crossover. These technical indicators suggest potential downside pressure, with Injective potentially breaching $7.5 and revisiting $7.1 if current momentum continues, though the new developments could help sustain demand and clear the $7.7 resistance level.
